國家衛生研究院 NHRI:Item 3990099045/10527
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 857790      在线人数 : 819
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/10527


    题名: Meglitinides increase the risk of hypoglycemia in diabetic patients with advanced chronic kidney disease: A nationwide, population-based study
    作者: Wu, PC;Wu, VC;Lin, CJ;Pan, CF;Chen, CY;Huang, TM;Wu, CH;Chen, L;Wu, CJ;Consortium, The NRPB Kidney
    贡献者: Division of Health Services and Preventive Medicine
    摘要: The safety of short-acting meglitinides in diabetic patients with advanced chronic kidney disease (CKD) has not been widely reported.Diabetic patients with advanced CKD who had a serum creatinine level of > 6 mg/dL a hematocrit level of <== 28% and received erythropoiesis-stimulating agent treatment between 2000 and 2010, were included in this nationwide study in Taiwan.The outcomes of interest were defined as hypoglycemia and long-term mortality. The risks of hypoglycemia and death were analyzed using Cox proportional hazards models, with end-stage renal disease and anti-diabetic drugs as time-dependent variables.Fresh users and matched non-users of meglitinides (both n = 2,793) were analyzed. The use of meglitinides increased the risk of hypoglycemia (HR, 1.93; 95% CI, 1.56-2.39), as did sulfonylurea and insulin use. The hypoglycemic effect of meglitinides was consistent among patient subgroups stratified by the status of concomitant use of other oral anti-diabetic agents. Concomitant use of meglitinide and insuilin will incresase the hypoglycemic risk. Moreover, it was not the use of meglitinides, but the presence of hypoglycemia that predicted mortality. The function curve showed an insignificant trend towards increased hypoglycemic risk in patients aged > 62 and </= 33 years from the generalized additive model.This study suggests that the use of short-acting meglitinides could be associated with increased risk of hypoglycemia in diabetic patients with advanced CKD, especially in patients aged > 62 and </= 33 years. Meglitinide combined with insulin will increase hypoglycemia in patients with advanced CKD.
    日期: 2017-09
    關聯: Oncotarget. 2017 Sep;8(44):78086-78095.
    Link to: https://doi.org/10.18632/oncotarget.17475
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000412066700183
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85030309241
    显示于类别:[陳麗光] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    PUB28514729.pdf1070KbAdobe PDF326检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈